Sun Pharmaceutical Industries Limited
SUNPHARMA
Rangering i aksjer
#520
Sun Pharmaceutical Industries Limited, a leading generic pharmaceutical... Sun Pharmaceutical Industries Limited, a leading generic pharmaceutical enterprise, is dedicated to the research, development, production, and marketing of both proprietary and unbranded medicinal formulations, alongside active pharmaceutical ingredients (APIs), for distribution across India and international markets. Its extensive product range encompasses treatments for numerous therapeutic fields, including central nervous system disorders, dermatological conditions, cardiovascular diseases, oncology, ophthalmic care, neuropsychiatry, gastrointestinal issues, infectious diseases, diabetes management, pain relief, nutritional supplements, respiratory ailments, gynaecology, urology, orthopaedics, nephrology, and dental health, among others. The company additionally provides APIs crucial for the creation of anti-cancer drugs, peptides, steroids, sex hormones, and controlled substances. Its generic medications are available in various forms, such as tablets, capsules, injectables, inhalers, ointments, creams, and liquid preparations. Furthermore, Sun Pharma develops specialized medications and a variety of over-the-counter health products. The company was established in 1983 and operates from its headquarters in Mumbai, India.
Aksjekurs
$19.24
Sist synkronisert: 2026-10-19
Markedsverdi
$46.15B
Endring (1 dag)
-0.97%
Endring (1 år)
0.11%
Land
IN
Handel Sun Pharmaceutical Industries Limited (SUNPHARMA)
Kategori
Healthcare
Inntekter for Sun Pharmaceutical Industries Limited (SUNPHARMA)
Inntekter i Jun 2026 TTM: $1.76B
Ifølge Sun Pharmaceutical Industries Limited sine nyeste økonomiske rapporter er selskapets nåværende resultat $1.76B. I 2024 hadde selskapet et resultat på $1.33B, en økning sammenlignet med resultatet i 2023, som var $1.14B. Resultatet som vises på denne siden er resultat før renter og skatt, eller EBIT.
Inntektshistorikk for Sun Pharmaceutical Industries Limited fra 2004 til 2026
Inntekter ved slutten av hvert år
| År | Inntekter | Endre |
|---|---|---|
| 2026 (TTM) | $1.76B | 9.86% |
| 2025 | $1.61B | 21.21% |
| 2024 | $1.33B | 16.34% |
| 2023 | $1.14B | 93.65% |
| 2022 | $588.17M | 54.49% |
| 2021 | $380.72M | -42.58% |
| 2020 | $663.01M | 20.88% |
| 2019 | $548.49M | 3.41% |
| 2018 | $530.42M | -62.03% |
| 2017 | $1.40B | 40.80% |
| 2016 | $992.01M | -3.13% |
| 2015 | $1.02B | 33.99% |
| 2014 | $764.30M | -3.90% |
| 2013 | $795.33M | 20.15% |
| 2012 | $661.93M | 44.90% |
| 2011 | $456.82M | 45.01% |
| 2010 | $315.02M | -17.95% |
| 2009 | $383.94M | -3.94% |
| 2008 | $399.69M | 107.87% |
| 2007 | $192.27M | 43.47% |
| 2006 | $134.02M | 39.03% |
| 2005 | $96.39M | 9.76% |
| 2004 | $87.82M | 0.00% |
Inntekter for lignende selskaper eller konkurrenter
| Selskap | Inntekter | Forskjell i inntekter | Land |
|---|---|---|---|
| - | - |
DE
|
|
| - | - |
DE
|
|
| - | - |
JP
|
|
| - | - |
CH
|
|
| - | - |
CN
|
